Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The healthcare sector is evolving as traditional drug development meets revolutionary gene editing. Investors are now choosing between Axsome Therapeutics (NASDAQ:AXSM) and CRISPR Therapeutics (NASDAQ:CRSP) for their medical portfolios.

Axsome focuses on commercializing treatments for central nervous system disorders, while CRISPR is a leader in gene-based medicines using its flagship platform. Both companies are at critical stages of their development. They offer different risk and reward profiles for investors interested in the future of medicine and the biotech industry.

The case for Axsome Therapeutics

Axsome Therapeutics develops therapies for central nervous system (CNS) conditions including depression, migraine, and narcolepsy. It currently markets medicines such as AUVELITY and SUNOSI in the United States, with SUNOSI also reaching international markets. In June 2026, the company settled patent litigation for SUNOSI, which helps clear the path for its continued commercial focus among biotech stocks.

In FY 2025, revenue reached nearly $638.5 million, representing a significant increase from the previous year. This growth of approximately 65.5% was driven by the strong commercial uptake of its leading CNS products. Despite this rising revenue, the company reported a net margin of negative 28.7%, resulting in a net loss of roughly $183.2 million for the period.

As of its December 2025 balance sheet, the debt-to-equity ratio is 2.7x, which measures total debt against the value of shareholder equity. The current ratio is roughly 1.6x, indicating the company's ability to cover short-term debts with its current assets. Free cash flow for the year was negative $93.9 million, representing the cash used in operations and the expansion of its product pipeline.

The case for CRISPR Therapeutics

CRISPR Therapeutics focuses on creating gene-based medicines using its proprietary CRISPR/Cas9 platform. Its most notable success is CASGEVY, an approved therapy for sickle cell disease and transfusion-dependent beta thalassemia. The company relies heavily on its partnership with Vertex (NASDAQ:VERX), as Vertex holds the primary responsibility for the global commercialization of this pioneering treatment.

In FY 2025, revenue reached roughly $3.5 million, which represents a decrease of nearly 90% compared to the prior year. This decline reflects a shift away from large one-time collaboration payments toward the early, more gradual stages of product commercialization. For the fiscal year, the company reported a net margin of negative 16,569.8% and a net loss of approximately $581.6 million.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.2x, which indicates a low level of debt relative to shareholder equity. The current ratio is approximately 13.3x, showing a very high level of liquidity and short-term financial flexibility. Free cash flow was negative $345.9 million, as the company continues to invest heavily in its research and clinical programs.

Risk profile comparison

Axsome Therapeutics faces risks related to its ongoing losses and high capital requirements for its various pipeline candidates. The company depends on the continued commercial success of a limited number of products like AUVELITY and SUNOSI. It also faces intense competition in the CNS disorder market from major players like Pfizer (NYSE:PFE), alongside potential impacts from evolving trade policies and regulatory environments.

CRISPR Therapeutics is highly dependent on the success of CASGEVY and its strategic partnership with Vertex. The pioneering nature of gene editing involves long-term safety questions and high manufacturing complexity that could affect future growth. Furthermore, the company must navigate a contested patent landscape and the need for additional capital to fund its extensive research and development without a guarantee of profitability.

Valuation comparison

Axsome features a lower P/S ratio relative to sales, while CRISPR offers a lower Forward P/E relative to future earnings estimates.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with CRISPR Therapeutics, though Axsome makes this closer than it might seem. Axsome has drugs on the market and growing revenue, and a new FDA approval for Alzheimer's agitation adds a new indication to its commercial portfolio. For investors who prefer owning a company already generating revenue at scale, it has a credible story.

But CRISPR is doing remarkable work that very few biotech companies have ever done. It has turned a gene-editing platform into an approved, commercially successful therapy. CASGEVY, its treatment for sickle cell disease and a related blood disorder, just received FDA approval for children as young as two years old, dramatically expanding the pool of eligible patients. Revenue is accelerating, losses are narrowing, and the company has enough cash to fund operations for years without raising more money.

The pipeline beyond CASGEVY is expanding into cardiovascular disease and other areas, adding long-term optionality that Axsome simply can't match right now. For a long-term investor comfortable with biotech risk, CRISPR is the stronger pick.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics and Pfizer. The Motley Fool recommends CRISPR Therapeutics. The Motley Fool has a disclosure policy.